Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : WHO sets dates for reviews of Sinopharm and Sinovac COVID-19 vaccines

04/22/2021 | 08:40am EDT
Booth displaying a coronavirus vaccine candidate from Sinovac Biotech Ltd is seen at the 2020 China International Fair for Trade in Services (CIFTIS), following the COVID-19 outbreak, in Beijing

GENEVA (Reuters) - Technical experts at the World Health Organization (WHO) will review on April 26 Chinese drugmaker Sinopharm's COVID-19 vaccine for possible emergency use listing, to be followed by the Sinovac jab on May 3, the agency said on Thursday.

"We would expect a decision a couple of days later," the WHO said in response to a Reuters query.

So far COVID-19 vaccines made by Pfizer AstraZeneca and Johnson & Johnson have received a WHO listing - an endorsement of their safety and efficacy that helps to guide countries' regulatory agencies.

(Reporting by Stephanie Nebehay; Editing by David Goodman)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.59% 8467 Delayed Quote.14.90%
SINOVAC BIOTECH LTD. -0.31% 6.47 Delayed Quote.0.00%
All news about ASTRAZENECA PLC
08:08aUPDATE3 : Japan to donate millions more AstraZeneca vaccine doses across Asia
AQ
05:44aSanofi-Regeneron Secures Two New Cancer Nods for Libtayo Amid Rising Competit..
MT
06/24Japan to give 6 mln doses of vaccines to Taiwan, 5 SE Asia nations
RE
06/24ASTRAZENECAá : Japan to give 1 mln doses of vaccine each to Taiwan, Vietnam, say..
RE
06/24THE LATEST : Thousands of vaccines set to expire in Romania
AQ
06/24WH Smith moves to pacify investors angered over executive pay
RE
06/24Swiss health ministry data shows vaccinated people seldom hit by COVID-19
RE
06/24EU slightly cuts estimates for vaccine deliveries this year
RE
06/24WHO estimates COVID-19 boosters needed yearly for most vulnerable
RE
06/24ASTRAZENECAá : 30 Covid-19 Deaths in Kenya as 622 New Cases Posted
AQ
More news
Financials (USD)
Sales 2021 30 988 M - -
Net income 2021 4 559 M - -
Net Debt 2021 10 731 M - -
P/E ratio 2021 36,9x
Yield 2021 2,44%
Capitalization 154 B 154 B -
EV / Sales 2021 5,31x
EV / Sales 2022 4,58x
Nbr of Employees 76 100
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Last Close Price 117,09 $
Average target price 132,44 $
Spread / Average Target 13,1%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC14.90%153 571
JOHNSON & JOHNSON3.81%428 269
ROCHE HOLDING AG11.02%323 588
PFIZER, INC.6.47%218 590
NOVARTIS AG1.71%207 904
ABBVIE INC.7.08%202 656